会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • RTVP BASED COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROSTATE CANCER
    • 基于RTVP的组合物和治疗前列腺癌的方法
    • WO0206344A2
    • 2002-01-24
    • PCT/US0118487
    • 2001-06-08
    • BAYLOR COLLEGE MEDICINETHOMPSON TIMOTHY CREN CHENGZHEN
    • THOMPSON TIMOTHY CREN CHENGZHEN
    • A61K38/00A61K39/00C07K14/47C07K14/705
    • C07K14/4747A61K38/00A61K39/00C07K14/705
    • This invention relates to a gene encoding RTVP that has been shown to be up-regulated by p53 using differential display-PCR and subsequently by co-transfection studies. RTVP-1 mRNA is abundant in normal mouse and human prostatic epithelial cells and primary tumors, but is significantly down regulated in metastatic mouse and human prostate cancer. In prostate cancer cells overexpression of the mouse RTVP-1 gene (mRTVP-1) induced apoptosis that was accompanied by increased caspase 8,9 and 3 activities. MRTVP-1-stimulated apoptosis was also associated with increased levels of bax, bad and activated BID; reduced levels of bcl-2 and bcl-XL; and cytosolic cytochrome c accumulation. Adenoviral-vector-mediated mRTVP-1 expression lead to potent growth suppression and antimetastatic activities in an orthotopic mouse model of prostate cancer in vivo . These therapeutic activities were associated with anti-angiogenic effects and importantly a local and systemic immune response. Accordingly, p53 was linked with suppression of metastasis through its induction of mRTVP-1, which can concurrently induce apoptosis, suppress agiogenesis and stimulate an antitumor immune response. Thus, the invention includes compositions and methods, based on RTVP nucleic acid, polypeptides, and antibodies, for use in the treatment, prevention and detection of neoplastic disease and, specifically, metastatic prostatic neoplasia.
    • 本发明涉及编码RTVP的基因,已被证明是通过差异显示PCR而被p53上调,随后通过共转染研究。 RTVP-1 mRNA在正常小鼠和人前列腺上皮细胞和原发性肿瘤中丰富,但在转移性小鼠和人前列腺癌中显着下调。 在前列腺癌细胞中,小鼠RTVP-1基因(mRTVP-1)的过度表达诱导凋亡,伴随着胱天蛋白酶8,9和3活性的增加。 MRTVP-1刺激的细胞凋亡也与bax,坏和活化的BID水平升高相关; 降低bcl-2和bcl-XL的水平; 和胞质细胞色素c积累。 腺病毒载体介导的mRTVP-1表达导致在体内前列腺癌的原位小鼠模型中有效的生长抑制和抗转移活性。 这些治疗活动与抗血管生成作用相关,重要的是局部和全身免疫应答。 因此,p53通过诱导mRTVP-1与抑制转移相关,可以同时诱导细胞凋亡,抑制生物发生和刺激抗肿瘤免疫反应。 因此,本发明包括基于RTVP核酸,多肽和抗体的组合物和方法,用于治疗,预防和检测肿瘤疾病,特别是转移性前列腺肿瘤。